HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John M D Storey Selected Research

Methylene Blue (Methylthioninium Chloride)

12/2016Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John M D Storey Research Topics

Disease

14Alzheimer Disease (Alzheimer's Disease)
09/2023 - 04/2014
4Atrophy
04/2022 - 01/2018
4Tauopathies
04/2022 - 04/2015
3Neurodegenerative Diseases (Neurodegenerative Disease)
03/2024 - 01/2017
2Parkinson Disease (Parkinson's Disease)
03/2024 - 01/2017
2Synucleinopathies
03/2024 - 01/2017
2Cognitive Dysfunction
04/2022 - 01/2019
1Frontotemporal Dementia (Semantic Dementia)
01/2020

Drug/Important Bio-Agent (IBA)

7hydromethylthionineIBA
09/2023 - 01/2017
6tau Proteins (tau Protein)IBA
04/2022 - 04/2015
2Amyloid (Amyloid Fibrils)IBA
11/2017 - 06/2015
2Proteins (Proteins, Gene)FDA Link
11/2017 - 01/2017
1alpha-SynucleinIBA
03/2024
1Rivastigmine (Exelon)FDA LinkGeneric
04/2022
1Cysteine (L-Cysteine)FDA Link
10/2018
1PrionsIBA
01/2018
1Glucose (Dextrose)FDA LinkGeneric
01/2018
1DisulfidesIBA
11/2017
1SynucleinsIBA
01/2017
1Methylene Blue (Methylthioninium Chloride)FDA Link
12/2016

Therapy/Procedure

9Therapeutics
03/2024 - 04/2014
2Activities of Daily Living (ADL)
01/2018 - 12/2016